Skip to content
value.today

Vyome Therapeutics Inc.

🇮🇳 Delhi, India, IndiaPharmaceuticalsFounded 2017
Total raised
$15 M
2 rounds on record
Latest round
$11 M
Dec 2018
First round on record
Dec 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vyome Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2018$11 MNo. 2$10 to $50 million

Vyome Therapeutics Inc.: Raise no. 2, Dec 2018

Investors in this round

9 investors had bought by the notice of Jan 3, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B-1, Series C-1, and Series D Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Venkateswarlu Nelabhotla · Executive Officer, Director, Promoter
  • Alab Rosling · Director
  • Bhaskar Chaudhari · Director
  • Chris Garabedian · Director
  • Krishna Gupta · Director
  • Kumar Shiraigi · Director
  • Mohanjit Jolly · Director
  • Shiladitya Sengupta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Venkateswarlu Nelabthotla, President, Treasurer, and Assistant Secretary. Source: SEC Form D, newest notice filed Jan 3, 2019. Read the notice at the SEC.

equitySEC
Dec 2018$3 MNo. 1$2 to $10 million

Vyome Therapeutics Inc.: Raise no. 1, Dec 2018

Investors in this round

6 investors had bought by the notice of Dec 28, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Venkateswarlu Nelabhotla · Executive Officer, Director, Promoter
  • Shiladitya Sengupta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Venkateswarlu Nelabhotla, President, Treasurer, and Assistant Secretary. Source: SEC Form D, newest notice filed Dec 28, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vyome Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2019).

    SEC Form D · Jan 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2019

That is all the official record says: Vyome Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vyome Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vyome Therapeutics Inc.
NameRoleNamed in
Venkateswarlu NelabhotlaExecutive officerJan 2019
Alab RoslingDirectorJan 2019
Bhaskar ChaudhariDirectorJan 2019
Chris GarabedianDirectorJan 2019
Krishna GuptaDirectorJan 2019
Kumar ShiraigiDirectorJan 2019
Mohanjit JollyDirectorJan 2019
Shiladitya SenguptaDirectorJan 2019
Venkateswarlu NelabhotlaDirectorJan 2019
Venkateswarlu NelabhotlaPromoterJan 2019